by Layba Camara M, Kagbadouno M, Kourouma A, Diallo M-B, Soumah A-M-M, Camara O, Mutumbo W, Ngolo D, Lubukulu G, Musawu Y, Ilboudo H, Bart J-M, Camara M, Kokolomami J. Santé Publique 2025, 37(2):173-184. doi: 10.3917/spub.252.0173
Summary: The authors of this study conducted an analytical cross-sectional study to assess the feasibility of launching fexinidazole for human African trypanosomiasis (HAT) in three endemic foci in Guinea (Boffa, Dubréka, and Forécariah). Nearly one in three respondents had good knowledge of how HAT is transmitted, and half had heard of the new treatment. Almost all respondents would readily accept oral HAT treatment and would be willing to take it at home. Many respondents would feel less stigmatized by following this treatment. Although the knowledge required, favourable attitude, and practices amenable to adopting this new treatment varied, depending on the study site and level of education, the respondents largely indicated that they would be confident in adopting this new treatment.
